Ariad Pharmaceuticals Inc fka ARIA

[glass_half_full]

He should cut a deal on Ponatanib and let's get in on with 113 and Bellicum and whatever else is in the lab.

From a business perspective, I don't think that could really expect to sell the broken part of your business.

The asset that Ariad holds that other pharmas can easily understand and value is '113. That's the thing that is on the auction block.

This is similar to when GM sold off Ally Bank. Their financing arm was the only segment turning a profit -- but that's not what GM does. GM (in theory) knows about car making, and anyone on the Street can value, buy and run a finance company. So you sell the banking operation, and use the funds to turn around the operation you specialize in.

Ariad's competitive advantage is (we think) thier lab. If Ariad really does have one actionable compound in the lab right now, they should sell or do a big-% partner of '113 for as much cash as possible.

Then they roll out their next candidate and try to get Iclusig back on the market. That's the turn-around plan.

Just some thoughts on how the b-school folks look at this.